Literature DB >> 20398056

Pitavastatin inhibits azoxymethane-induced colonic preneoplastic lesions in C57BL/KsJ-db/db obese mice.

Yoichi Yasuda1, Masahito Shimizu, Yohei Shirakami, Hiroyasu Sakai, Masaya Kubota, Kazuya Hata, Yoshinobu Hirose, Hisashi Tsurumi, Takuji Tanaka, Hisataka Moriwaki.   

Abstract

Obesity and related metabolic abnormalities are risk factors for colorectal cancer. A state of chronic inflammation and adipocytokine imbalance may play a role in colorectal carcinogenesis. Statins, which are commonly used for the treatment of hyperlipidemia, are known to possess anti-inflammatory effects. Statins also exert chemopreventive properties against various cancers. The present study examined the effects of pitavastatin, a recently developed lipophilic statin, on the development of azoxymethane (AOM)-initiated colonic premalignant lesions in C57BL/KsJ-db/db (db/db) obese mice. Male db/db mice were administrated weekly subcutaneous injections of AOM (15 mg/kg body weight) for 4 weeks and then were subsequently fed a diet containing 1 ppm or 10 ppm pitavastatin for 8 weeks. Feeding with either dose of pitavastatin significantly reduced the number of colonic premalignant lesions, beta-catenin accumulated crypts, by inhibiting proliferation and the surrounding inflammation. Pitavastatin increased the serum levels of adiponectin while conversely decreasing the serum levels of total cholesterol, tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-6, IL-18, and leptin. Pitavastatin also caused a significant increase in the expression of phosphorylated form of the AMP-activated kinase (AMPK) protein on the colonic mucosa of AOM-treated mice. In addition, the expression levels of TNF-alpha, IL-6, IL-18, and COX-2 mRNAs on the colonic mucosa of AOM-treated mice were decreased by treatment with this agent. These findings suggest that pitavastatin attenuates chronic inflammation and improves the imbalance of adipocytokines, both of which are caused by the presence of excess adipose tissues, thereby preventing the development of colonic premalignancies in an obesity-related colon cancer model. Therefore, some types of statins, including pitavastatin, may be a useful chemoprevention modality for colon cancer in obese individuals.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20398056     DOI: 10.1111/j.1349-7006.2010.01579.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  31 in total

1.  Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice.

Authors:  Altaf Mohammed; Li Qian; Naveena B Janakiram; Stan Lightfoot; Vernon E Steele; Chinthalapally V Rao
Journal:  Int J Cancer       Date:  2012-03-14       Impact factor: 7.396

2.  Impact of Dyslipidemia on the Risk of Second Cancer in Thyroid Cancer Patients: A Korean National Cohort Study.

Authors:  Joon Ho; Eunhwa Kim; Minkyung Han; Inkyung Jung; Jandee Lee; Young Suk Jo
Journal:  Ann Surg Oncol       Date:  2021-01-22       Impact factor: 5.344

Review 3.  Chemoprevention of obesity-related liver carcinogenesis by using pharmaceutical and nutraceutical agents.

Authors:  Hiroyasu Sakai; Yohei Shirakami; Masahito Shimizu
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

4.  Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk.

Authors:  Michael S Simon; Carol A Rosenberg; Rebecca J Rodabough; Phillip Greenland; Ira Ockene; Hemant K Roy; Dorothy S Lane; Jane A Cauley; Janardan Khandekar
Journal:  Ann Epidemiol       Date:  2011-11-04       Impact factor: 3.797

5.  The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study.

Authors:  Cathryn H Bock; Allison M Jay; Gregory Dyson; Jennifer L Beebe-Dimmer; Michele L Cote; Lifang Hou; Barbara V Howard; Pinkal Desai; Kristen Purrington; Ross Prentice; Michael S Simon
Journal:  Breast Cancer Res Treat       Date:  2017-10-24       Impact factor: 4.872

Review 6.  Obesity and cancer--mechanisms underlying tumour progression and recurrence.

Authors:  Jiyoung Park; Thomas S Morley; Min Kim; Deborah J Clegg; Philipp E Scherer
Journal:  Nat Rev Endocrinol       Date:  2014-06-17       Impact factor: 43.330

Review 7.  Chemoprevention of colorectal cancer by targeting obesity-related metabolic abnormalities.

Authors:  Yohei Shirakami; Masahito Shimizu; Masaya Kubota; Hiroshi Araki; Takuji Tanaka; Hisataka Moriwaki; Mitsuru Seishima
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 8.  Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer.

Authors:  Tae Il Kim
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

9.  Aldose reductase inhibition suppresses azoxymethane-induced colonic premalignant lesions in C57BL/KsJ-db/db mice.

Authors:  Ashish Saxena; Mohammad Shoeb; Ravinder Tammali; Kota V Ramana; Satish K Srivastava
Journal:  Cancer Lett       Date:  2014-09-10       Impact factor: 8.679

10.  Statin use is associated with a reduced incidence of colorectal adenomatous polyps.

Authors:  Thomas Broughton; Jamie Sington; Ian L P Beales
Journal:  Int J Colorectal Dis       Date:  2012-11-01       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.